{
  "id": "602344ab1cb411341a00008e",
  "type": "summary",
  "question": "What is the use of Lactin-V?",
  "ideal_answer": "Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower incidence of recurrence of bacterial vaginosis and can be used for bacterial vaginosis. Lactin-V after treatment for cystitis was associated with a reduction in recurrent UTI.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19543144",
    "http://www.ncbi.nlm.nih.gov/pubmed/20644497",
    "http://www.ncbi.nlm.nih.gov/pubmed/32402161",
    "http://www.ncbi.nlm.nih.gov/pubmed/21498386"
  ],
  "snippets": [
    {
      "text": "Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32402161",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "METHODS: We conducted a randomized, double-blind, placebo-controlled, phase 2b trial to evaluate the ability of Lactobacillus crispatus CTV-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32402161",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: The use of Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32402161",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We conducted a double-blind placebo-controlled trial of a Lactobacillus crispatus intravaginal suppository probiotic (Lactin-V; Osel) for prevention of recurrent UTI in premenopausal women.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498386",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Lactin-V after treatment for cystitis is associated with a reduction in recurrent UTI. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498386",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: A phase 2a study assessed colonization efficiency, safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) administered by a vaginal applicator.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: LACTIN-V colonized well, and was safe and acceptable in women treated for BV.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20644497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19543144",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "SIONS: Lactin-V after treatment for cystitis is associated with a reduction in recurrent UTI. Large",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498386",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "-level vaginal colonization with L. crispatus (\u226510(6) 16S RNA gene copies per swab) throughout follow-up was associated with a significant reduction in recurrent UTI only for Lactin-V (RR for Lactin-V, .07; RR for placebo, 1.1; P < .01).CONC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21498386",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}